Advances in Ultrasound-Responsive Radiopharmaceutical Systems for the Management of Ocular Malignancies
Yingying Ye1,2
1National Engineering Research Centre of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
Abstract:
Ocular malignancies provide a unique therapeutic challenge because of their anatomical intricacy, limited accessibility, and vision-critical nature. Recent developments in radiopharmaceutical design have been paired with ultrasound-mediated medicine administration to create highly targeted, less invasive therapies for intraocular cancers. This research looks at the emerging topic of ultrasound-responsive radiopharmaceutical devices built specifically for ocular oncology. These methods enhance tumor selectivity, decrease off-target effects, and enable real-time imaging-guided therapy by utilizing targeted ultrasound to induce localized medication release or radiotherapeutic agent activation. Microbubble-assisted delivery, thermosensitive liposomes, and phase-transition nanodroplets carrying radionuclides have all been designed to optimize ocular pharmacokinetics and tissue penetration. Preclinical studies reveal promising results in increasing radiotherapeutic efficacy against retinoblastoma and uveal melanoma while sparing healthy ocular tissues.
Insights
New ultrasound-responsive radiopharmaceuticals offer targeted, less invasive treatment for intraocular cancers. These advanced therapies improve tumor selectivity and spare healthy ocular tissues, showing promise for retinoblastoma and uveal melanoma.
Area of Science:
- Ocular oncology
- Radiopharmaceutical therapy
- Ultrasound-mediated drug delivery
Background:
- Ocular malignancies present unique therapeutic challenges due to anatomical complexity and vision criticality.
- Traditional treatments often lack specificity and can cause significant side effects.
- Recent advancements integrate radiopharmaceutical design with ultrasound for targeted intraocular cancer therapies.
Purpose of the Study:
- To explore emerging ultrasound-responsive radiopharmaceutical devices for ocular oncology.
- To evaluate methods enhancing tumor selectivity and reducing off-target effects in intraocular cancers.
- To assess the potential for real-time imaging-guided therapy using targeted ultrasound for localized drug release or radiotherapeutic activation.
Main Methods:
- Development of ultrasound-responsive radiopharmaceutical devices, including microbubble-assisted delivery, thermosensitive liposomes, and phase-transition nanodroplets carrying radionuclides.
- Optimization of ocular pharmacokinetics and tissue penetration for targeted delivery.
- Utilizing targeted ultrasound to trigger localized release or activation of therapeutic agents.
Main Results:
- Preclinical studies demonstrate enhanced tumor selectivity and reduced damage to healthy ocular tissues.
- Promising efficacy observed in treating retinoblastoma and uveal melanoma.
- Real-time imaging guidance enables precise therapeutic delivery.
Conclusions:
- Ultrasound-responsive radiopharmaceuticals represent a significant advancement in ocular oncology.
- These targeted therapies offer a less invasive and more effective treatment approach for intraocular cancers.
- Further research holds potential for improved patient outcomes in treating conditions like retinoblastoma and uveal melanoma.
More Related Videos
08:02A High-Throughput Image-Guided Stereotactic Neuronavigation and Focused Ultrasound System for Blood-Brain Barrier Opening in Rodents
Published on: July 16, 2020
05:46Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
